Lomitapide/Strong or Moderate CYP3A4 Inhibitors Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Very Serious. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may slow down how quickly your liver processes lomitapide.
What might happen:
The amount of lomitapide in your blood may increase and cause more side effects than normally expected.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know as soon as possible that you are taking these medicines together. Your doctor may want to discontinue or adjust the dose of your lomitapide while you are taking your other medicine.Let your doctor know right away if you have any pain or discomfort in the upper right stomach (abdominal) area, yellowing of the skin or eyes, loss of appetite, nausea or vomiting, fever or dark/amber-colored urine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Juxtapid (lomitapide) US prescribing information. Aegerion Pharmaceuticals, Inc. May, 2016.
- 2.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
- 3.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
- 4.Sporanox (itraconazole) US prescribing information. Janssen Pharmaceutica Products, L.P. December, 2022.
- 5.Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir) US prescribing information. Gilead Sciences, Inc. September, 2021.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.